The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

Inclusion Criteria: * Willing and able to provide written informed consent * Subjects Age ≥ 18 * Initial SARS-CoV-2 infection confirmed by PCR test or positive serologies * Have findings consistent with interstitial lung disease found on CT scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) * Required one of the following after diagnosis with SARS-CoV-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as CPAP or BIPAP, or mechanical ventilation or a history of desaturation below 90% * Are at least 30 days from onset of initial SARS-CoV-2 symptoms * Forced Vital Capacity less than or equal to 90% predicted based on ATS/ERS criteria or DLCO less than or equal to 70% * Women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib Exclusion Criteria: Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of the Screening Visit (prior to randomization): * Co-administration of other investigational agents against COVID-19 * Active SARS-CoV-2 infection based on clinical judgment * Currently Pregnant or Breast Feeding * Current Use of Prednisone or equivalent \> 10 mg/daily or immunosuppressive therapy or disease modifying agents * Use of full dose anticoagulation therapy or high dose anti platelet drug therapy at scre…